MK-8353

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Colorectal CancerNeoplasmsSolid TumorsTumor, Solid

Phase 1

A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)

TerminatedNCT01358331

Merck Sharp & Dohme LLCTumor, Solid

Start: 2011-11-04End: 2014-05-20Updated: 2020-04-02

Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)

TerminatedNCT02972034

Merck Sharp & Dohme LLCColorectal Cancer, Neoplasms

Start: 2017-01-13End: 2022-12-02Updated: 2024-11-21

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

CompletedNCT03745989

Merck Sharp & Dohme LLCSolid Tumors

Start: 2019-02-22End: 2021-03-19Updated: 2023-07-27

Related Papers

A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors

Investigational New Drugs2024-09-143 citations

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

2023-04-1111 citations

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

2018-02-22104 citations